Key Highlights
- 0.13 USD is the per-share loss built into the consensus EPS estimate of -0.13 for TuHURA Biosciences, Inc. (NASDAQ:HURA), due to report third-quarter 2026 results ahead of the opening bell on November 13, 2026.
- 8.7 million USD is the combined second-quarter 2026 outlay on R&D of USD 6.6 million and G&A of USD 2.1 million, against USD 4.9 million and USD 1.9 million in the prior-year period.
- 1.0 million USD was the cash on hand on June 30, 2026, while a USD 50 million Royalty transaction and Credit Facility with the biggest Shareholder is meant to stretch the runway into 2028.
- 96.86 million USD is the Market Value in the screening snapshot, under USD 100 million, set against about 63.7 million shares outstanding on June 30, 2026, which prompts small-cap questions on Liquidity and dilution.
What Canadian Investors Can Expect From TuHURA Biosciences, Inc. (NASDAQ:HURA) on November 13, 2026
The screening snapshot has TuHURA Biosciences, Inc. publishing third-quarter 2026 results before the opening bell on November 13, 2026, with a consensus EPS estimate of -0.13 and a market value of USD 96.86 million. Combined second-quarter operating costs of USD 8.7 million (calculated), spread across about 63.7 million shares, work out to roughly USD 0.14 per share (calculated), near the estimate. Coverage did not provide a second-quarter net loss or per-share figure, nor a prior-year third-quarter comparison.
Latest Quarter Results and Management Outlook at TuHURA Biosciences, Inc. (NASDAQ:HURA)
Second-quarter 2026 R&D spending increased by USD 1.7 million to USD 6.6 million because of clinical activity, while G&A grew by USD 0.3 million to USD 2.1 million driven by Stock Compensation and the cost of being a listed company. Cash used in operations over six months came to USD 13.0 million, up from USD 10.9 million, partly balanced by financing inflows of USD 10.6 million against USD 8.1 million. Management anticipates orphan-drug status for IFx-2.0 in Merkel cell carcinoma in second-half 2026, early investigator-study data in first-half 2027 and completed Phase 3 enrollment in second-half 2027. TBS-2025 is due to begin a Phase 1b/2 study in AML in second-half 2026.
Liquidity, Valuation and Risk Factors at TuHURA Biosciences, Inc. (NASDAQ:HURA)
USD 1.0 million of cash set beside USD 13.0 million of operating cash use over six months leaves near-term funding reliant on drawing the facility. The facility carries 12% interest payable every month, with the principal falling due on April 21, 2031, and just USD 5.7 million had arrived, USD 2.15 million of it after June 30, 2026. At-the-market sales brought in USD 0.3 million in April and USD 0.1 million in July. With a market value under USD 100 million, nano-cap and small-cap shares may be volatile and hard to trade, so trial setbacks, dilution and related-party financing stand out as key risks.
Where Things Stand
TuHURA Biosciences, Inc. (NASDAQ:HURA) heads into its report with a consensus EPS estimate of -0.13, a snapshot market value of USD 96.86 million and USD 1.0 million of cash on June 30, 2026. Management presents a USD 50 million facility as lengthening the runway into 2028, though only USD 5.7 million had come in by mid-August. Clinical milestones for IFx-2.0 and TBS-2025 bunch up across second-half 2026 and first-half 2027, so updates on financing and timing may dominate the call. The snapshot does not confirm a call time. This note is for information only and is not a recommendation to buy or sell.



_11_17_2026_19_45_07_327614.jpg)
_11_17_2026_18_59_44_560836.jpg)

Please wait processing your request...